Adams Develops New Guaifenesin Products As Mucinex Growth Continues

Adams Respiratory Therapeutics will file an NDA before the end of the year for a product combining the firm's 12-hour extended-release guaifenesin with another respiratory ingredient to create a new, patented combination drug